Apogee Therapeutics Boosts Cash Reserves to $902.9M

By Chris Stiles • Monday, March 02 10:54 • Permanent Link

Apogee Therapeutics, Inc. (NASDAQ: APGE) has reported its full year 2025 financial results, showing significant progress in its pipeline and a strong financial position. The company's total cash position stood at $902.9 million as of December 31, 2025, marking an increase from $731.1 million as of December 31, 2024. This substantial cash reserve is expected to support the company's operations into the second half of 2028.

Research and development (R&D) expenses for the year ended December 31, 2025, totaled $214.7 million, up from $167.9 million for the year ended December 31, 2024. The increase in R&D expenses primarily reflects the advancement of the pipeline, continued development of the company’s programs, increases in personnel-related expenses, and equity-based compensation associated with the growth in the company's R&D team.

General and administrative (G&A) expenses amounted to $70.9 million for the year ended December 31, 2025, compared to $49.0 million for the year ended December 31, 2024. This increase is attributed to rises in personnel-related expenses and equity-based compensation, driven by increased headcount and an increase in the fair value of equity awards granted, resulting from the company's expansion of operations to support its business growth.

The net loss for the year ended December 31, 2025, was $255.8 million, up from $182.1 million for the year ended December 31, 2024. This increase in net loss is primarily due to higher R&D and G&A expenses.

In terms of pipeline progress, Apogee Therapeutics highlighted its advancements in the development of Zumilokibart (APG777) for the treatment of atopic dermatitis (AD) and other indications. The company is expecting 52-week part A data from the Apex Phase 2 clinical trial of Zumilokibart for AD this month, with 16-week part B data anticipated in the second quarter of 2026. Additionally, the company plans to initiate Phase 3 trials of Zumilokibart in AD in the second half of 2026.

The Phase 1b head-to-head study of APG279 (Zumilokibart + APG990) against Dupixent in AD is also progressing, with results expected in the second half of 2026. Furthermore, Apogee Therapeutics aims to disclose its plans to advance APG273 (Zumilokibart + APG333) in respiratory indications in 2026.

The market has reacted to these announcements by moving the company's shares 0.03% to a price of $80.77. For the full picture, make sure to review Apogee Therapeutics's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.